Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Syneron Candela Leads Energy Innovation Discussions at 36th Annual ASLMS Conference

Industry-leading Physicians Present 11 Abstracts Highlighting Performance and Ease-of-Use of PicoWay, CO2RE, elos® and Profound Technologies


News provided by

Syneron Medical Ltd.

Mar 31, 2016, 09:00 ET

Share this article

Share toX

Share this article

Share toX

IRVINE, California, March 31, 2016 /PRNewswire/ --

Continue Reading

Syneron Medical Ltd. (NASDAQ: ELOS) a global leader in aesthetic medical devices, today announced the presentation of 11 scientific abstracts at the Annual Conference of the American Society of Laser Medicine and Surgery (ASLMS). During the conference, industry luminaries will present new and breakthrough findings demonstrating safety and efficacy from clinical studies using Syneron Candela technologies for treating skin pigmentations, removing tattoos, removing hair and restoring vaginal health. The 36th annual conference will take place March 30 through April 3, 2016 at the Sheraton Boston Hotel/Hynes Convention Center in Boston, Mass.

     (Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

Seven abstracts will demonstrate the performance of the brand's customizable, picosecond PicoWay® lasers for the removal of tattoos from an array of skin types, the correction of skin pigmentation and histological findings showing the effects of photoacoustic treatments on skin. Additional abstracts focus on the efficacy of permanent laser hair removal featuring the combination of an alexandrite 755nm laser with the award-winning elos® technology as well as impressive results from a study on Profound®, the first microneedle based fractional radiofrequency device to have a 100 percent response rate for rebuilding collagen, elastin and hyaluronic acid. Two abstracts will feature the company's established CO2RE platform, offering a range of solutions for resurfacing, wrinkle and scar reduction, pigmentation correction, and now the newly released CO2RE® Intima treatment, for restoring vaginal health.

"We have been developing, innovating and advancing energy based devices for more than four decades," said Dr. Shimon Eckhouse, Chairman of the Board, Syneron Candela. "With our experience, strong IP position and know-how, we have the ability to continuously innovate across our portfolio, anticipating trends and presenting our customers with the most advanced, highly-effective systems available. The strong clinical results presented at ASLMS prove that Syneron Candela continues to deliver scientific innovation, clinical excellence and great business opportunities for our customers."

Syneron Candela's ultrasound based UltraShape body shaping system will also be discussed at a variety of conference forums including the Non-Invasive Body Contouring Workshop and the Non-Invasive Body Contouring segment during the Annual ASLMS Tech Connect programs. All of the Syneron Candela products can be seen at the Syneron Candela booth #201.

Presentations on the company's leading picosecond technology are as follows:

Title: Novel Method for Treatment of Melasma with a 532nm Picosecond Laser
Author: David Friedman, Dr. David Friedman Skin & Laser Center, Jerusalem, Israel
Date and Time: Friday, April 1 at 1:00 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: LB4

Title: Comparison Study of a 532/1064nm Picosecond Laser vs. a 532/1064nm Nanosecond Laser in the Treatment of Multi-Colored Tattoos in Asians and Comparison Study of a 532/1064nm Picosecond Laser vs. a 532/1064nm Nanosecond Laser in the Treatment of Black Tattoos in Asians
Authors: Taro Kono, Samantha Shek, Henry Chan, William Groff, Kotaro Imagawa, Muneo Miyasaka; Tokai University, Isehara, Japan; University of Hong Kong, Hong Kong, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA; Cosmetic Laser Dermatology, San Diego, CA
Date and Time: Friday, April 1 at 1:07 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: 38A/B

Title: A Single Center Cohort Study for the Removal of Tattoos and Pigmented Lesions Using a 1064/532nm Dual Wavelength Picosecond Laser
Authors: Thomas Proebstle; University Medical Center Mainz, Mainz, Germany
Date and Time: Friday, April 1 at 1:21 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: 39

Title: Comparison Study of a 532nm Picosecond Laser vs. a 532nm Nanosecond Laser in the Treatment of Pigmented Lesions in Asians
Authors: Taro Kono, Samantha Shek, Henry Chan, William Groff, Kotaro Imagawa, Muneo Miyasaka; Tokai University, Isehara, Japan; University of Hong Kong, Hong Kong, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA; Cosmetic Laser Dermatology, San Diego, CA
Date and Time: Friday, April 1 at 1:28 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: 40

Title: Dual Wavelength Picosecond Laser Tattoo Removal: A Blinded Multi-Center Study
Authors: Tina Alster, Arielle Kauvar, Eric Bernstein; Washington Institute of Dermatologic Laser Surgery, Washington, DC; New York Laser and Skin Care, New York, NY; Main Line Center for Laser Surgery, Ardmore, PA
Date and Time: Friday, April 1 at 1:49 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: 36

Title: Histologic Evaluation of In Vivo Human Skin Following Fractioned Treatment with High Intensity 1064 and 532nm Picosecond Pulses
Authors: Arielle Kauvar, Kevin Schomaker, Tuvia Dror-Kutcher, Jayant Bahwalker, Ruthie Amir; New York Laser & Skin Care, NY; Syneron Candela, Yokneam, Israel
Date and Time: Friday, April 1 at 3:42 p.m.
Sessions: Cutaneous Applications - Picosecond
Location: Hynes Auditorium
Abstract: LB7

The Profound presentation will be featured as follows:

Title: Clinical Trial Assessing Treatment with Microneedle-based Fractional Radiofrequency for Cellulite
Authors: Leyda Bowes, Miami, FL
Date and Time: Saturday, April 2 at 3:51 p.m.
Sessions: Cutaneous Applications - New Devices and Novel Data for Body Contouring
Location: Hynes Auditorium
Abstract: 59

Abstracts featuring the company's established CO2RE platform will be presented in the two sessions below:

In the first session, César Arroyo, M.D. will discuss clinical trial results from a CO2RE Intima study resulting in proven remodeling of vaginal and vulvar tissue and a 94% patient satisfaction rate.

"I led the initial clinical study on CO2RE Intima at H. M. Monteprincipe Hospital in Madrid. Of the 21 women treated, 94 percent were satisfied with the treatment, which is a very high satisfaction rate for an aesthetic procedure," said César Arroyo, M.D. "I have had previous experience using other technologies for this type of vaginal treatment, both Er:YAG and radiofrequency. I found the CO2 technology of CO2RE Intima to be a more effective treatment because it both ablates and coagulates providing the type of fractional impact that is most effective on mucosal tissue. In addition, it can be used to treat all three areas: vaginal canal, introitus and vulva."

Title: Sexual Function and Overall Satisfaction after Fractional CO2 Laser Vaginal Rejuvenation Treatment in Premenopausal Women: A Pilot Study & Short Term Results
Authors: César Arroyo, Ruthie Amir, Konika Schallen; Hospital Monteprincipe, Madrid, Spain; Syneron Medical, Yokneam, Israel; Syneron Medical, Jacksonville, FL
Date and Time: Saturday, April 2 at 4:30 p.m.
Sessions: Women's Health - Pelvic Floor Dysfunction
Location: Hynes 107
Abstract: 185

Title: Histological Evaluation for Laser Depth of Ex Vivo Abdominoplasty Skin Following Fractionated Treatment with a High Intensity Traditional, Fractional and Fusion Carbon Dioxide Laser
Authors: Jill Waibel, Adam Wulkan, Ashley Rudnik; Miami Dermatology and Laser Institute; University of Miami, Miami, FL
Date and Time: Sunday, April 3 at 7:23 a.m.
Sessions: Cutaneous Applications - Advances in Fractionated Devices & Late Breaking
Location: Hynes Auditorium
Abstract: LB17

Finally a presentation on the combination of alexandrite laser and elos® technologies, a first, will be evaluated for its efficacy on permanent hair reduction.

Title: Long Term Follow up Using a Recently Developed Radiofrequency Energy - Alexandrite Laser Hair Removal Device
Authors: Jerome Garden, Megan Calderon, Pedram Gerami; Northwestern University; Physicians Laser and Dermatology Institute, Chicago, IL
Date and Time: Sunday, April 3 at 8:43 a.m.
Sessions: Cutaneous Applications - Advances in Fractionated Devices & Late Breaking
Location: Hynes Auditorium
Abstract: LB21

About ASLMS 

The American Society for Laser Medicine and Surgery, Inc. (ASLMS) is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.

About Syneron Candela 

Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS 

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contacts:
Corporate Contact
[email protected]

Media Contact
Lindsay LeCain
+1-617-986-5706
[email protected]

SOURCE Syneron Medical Ltd.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.